MS

While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
Endpoints
Novartis
FDA
Gilenya
MS
multiple sclerosis
Mylan
Dr Reddy's
Torrent Pharmaceuticals
Aurobindo
generics
Flag link:
Treating multiple sclerosis with the help of the gut microbiome
Treating multiple sclerosis with the help of the gut microbiome
Fierce Biotech
Brigham and Women's
microbiome
microRNA
multiple sclerosis
MS
Flag link:
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Motley Fool
Biogen
MS
multiple sclerois
Alzheimer's disease
Tecfidera
aducanumab
Flag link:
Patient charity to pay $4M to settle kickback allegations
Patient charity to pay $4M to settle kickback allegations
Beckers Hospital Review
kickbacks
Medicare
Medicare fraud
MS
multiple sclerosis
Teva Pharmaceutical
Biogen
Novartis
Flag link:
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
MS
multiple sclerosis
physicians
Novartis
Mayzent
Merck KGaA
Mavenclad
Biogen
Vumerity
Flag link:
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Multiple Sclerosis News Today
Biogen
MS
multiple sclerosis
Vumerity
drug pricing
Tecfidera
Flag link:
Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Endpoints
Biogen
Alkermes
FDA
multiple sclerosis
MS
Vumerity
Flag link:
Why People With MS Need Permission from Insurers To Take Life-Saving Drugs. It’s Not The Reason You Think.
Why People With MS Need Permission from Insurers To Take Life-Saving Drugs. It’s Not The Reason You Think.
Forbes
MS
multiple sclerosis
patients
insurers
payers
drug pricing
Flag link:
A new company enters the Tecfidera fight, offering to kill two birds
A new company enters the Tecfidera fight, offering to kill two birds
Endpoints
Biogen
Tecfidera
MS
flushing
Vitalis Pharmaceuticals
Flag link:
Sanofi breaks into digital therapeutics with mental health app for MS patients
Sanofi breaks into digital therapeutics with mental health app for MS patients
Fierce Pharma
Sanofi
digital therapeutics
Happyify Health
MS
multiple sclerosis
Flag link:
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Fierce Pharma
Biogen
Tecfidera
MS
multiple sclerosis
Flag link:
Does competition equal lower prices? MS drugs defied cost logic as challengers swarmed in
Does competition equal lower prices? MS drugs defied cost logic as challengers swarmed in
Fierce Pharma
multiple sclerosis
MS
drug pricing
Biogen
Roche
Sanofi
Novartis
Teva Pharmaceutical
Bayer
Flag link:
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Biopharma Dive
drug pricing
MS
multiple sclerosis
Medicare
Flag link:
Tackling the remaining challenges of multiple sclerosis
Tackling the remaining challenges of multiple sclerosis
Pharmaforum
Merck KGaA
MS
multiple sclerosis
evobrutinib
Flag link:
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
Flag link:
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
Endpoints
Biogen
Alkermes
MS
multiple sclerosis
Vumerity
clinical trials
Flag link:
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Flag link:
German Merck finally gets yes for MS drug Mavenclad
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:

Pages